US FDA approves Lilly's breast cancer drug combo - Reuters
US FDA approves Lilly's breast cancer drug combo Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOTXlJZ0pUc3JoMHBCd2tEY2N5NWxsbHRXTFZFQ0RVaXRzV0UxZEM2TFNMcjVWUldkaUFaandZbHIxVmRqaUV3b2tPUzRKV3BPZ281TlRMblRGeTlZdjBrb1o3M0xnaHpEV1NyaExrdkFSSkFZcUJndVBQS2FGMHJwSXdJajlmZDV3amYzN2xRYVZZTWxlX1dscllPSjJDYWRxekE?oc=5" target="_blank">US FDA approves Lilly's breast cancer drug combo</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMViatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters
October 8, 2026 at 02:39 PMGate Bioscience expands Lilly drug discovery deal worth more than $870 million - Reuters
Gate Bioscience expands Lilly drug discovery deal worth more than $870 million Reuters
October 5, 2026 at 01:55 PMCSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis - Reuters
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Reuters
October 4, 2026 at 10:18 PMAbbVie joins US government pilot to test drug discount rebates - Reuters
AbbVie joins US government pilot to test drug discount rebates Reuters
October 2, 2026 at 08:53 PM